The DOI matches its Crossref record; 670 of the 670 references it cites were found in a registry or an index.
Harnessing innate immune pathways for therapeutic advancement in cancer
Open accessAbstract
The innate immune pathway is receiving increasing attention in cancer therapy. This pathway is ubiquitous across various cell types, not only in innate immune cells but also in adaptive immune cells, tumor cells, and stromal cells. Agonists targeting the innate immune pathway have shown profound changes in the tumor microenvironment (TME) and improved tumor prognosis in preclinical studies. However, to date, the clinical success of drugs targeting the innate immune pathway remains limited. Interestingly, recent studies have shown that activation of the innate immune pathway can paradoxically promote tumor progression. The uncertainty surrounding the therapeutic effectiveness of targeted drugs for the innate immune pathway is a critical issue that needs immediate investigation. In this review, we observe that the role of the innate immune pathway demonstrates heterogeneity, linked to the tumor development stage, pathway status, and specific cell types. We propose that within the TME, the innate immune pathway exhibits multidimensional diversity. This diversity is fundamentally rooted in cellular heterogeneity and is manifested as a variety of signaling networks. The pro-tumor effect of innate immune pathway activation essentially reflects the suppression of classical pathways and the activation of potential pro-tumor alternative pathways. Refining our understanding of the tumor’s innate immune pathway network and employing appropriate targeting strategies can enhance our ability to harness the anti-tumor potential of the innate immune pathway and ultimately bridge the gap from preclinical to clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 601–670 of 670
Profound tumor-specific Th2 bias in patients with malignant glioma
Shimato, S., Maier, L. M., Maier, R., Bruce, J. N., Anderson, R. C. E., & Anderson, D. E. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-561 · Cited by 35
Bertin, S., Samson, M., Pons, C., Guigonis, J., Gavelli, A., Baqué, P., Brossette, N., Pagnotta, S., Ricci, J., & Pierrefite‐Carle, V. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800100-mcp200 · Cited by 35
Biased signalling is an essential feature of TLR4 in glioma cells
Zeuner, M.-T., Krüger, C. L., Volk, K., Bieback, K., Cottrell, G. S., Heilemann, M., & Widera, D. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.09.016 · Cited by 35
Zanker, D. J., Spurling, A., Brockwell, N. K., Owen, K. L., Zakhour, J. M., Robinson, T., Duivenvoorden, H. M., Hertzog, P. J., Mullins, S., Wilkinson, R. W., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1177 · Cited by 35
Roßmann, L., Bagola, K., Stephen, T., Gerards, A.-L., Walber, B., Ullrich, A., Schülke, S., Kamp, C., Spreitzer, I., Hasan, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103651118 · Cited by 35
Zhang, Y., Li, N., Yuan, G., Yao, H., Zhang, D., Li, N., Zhang, G., Sun, Y., Wang, W., Zeng, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02248-w · Cited by 35
Liu, C., He, D., Zhang, S., Chen, H., Zhao, J., Li, X., & Zeng, X. Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.839460 · Cited by 35
Daniel, W. L., Lorch, U., Mix, S., & Bexon, A. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1073777 · Cited by 35
Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression
Papafragkos, I., Grigoriou, M., Boon, L., Kloetgen, A., Hatzioannou, A., & Verginis, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889075 · Cited by 34
Park, S. N., Noh, K. T., Jeong, Y.-I., Jung, I. D., Kang, H. K., Cha, G. S., Lee, S. J., Seo, J.-K., Kang, D. H., Hwang, T.-H., et al. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.14 · Cited by 33
Liu, B., Sun, R., Luo, H. R., Liu, X., Jiang, M., Yuan, C., Yang, L., & Hu, J. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.10.002 · Cited by 33
RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation
Engel, C., Brügmann, G., Lambing, S., Mühlenbeck, L. H., Marx, S., Hagen, C., Horváth, D., Goldeck, M., Ludwig, J., Herzner, A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0129-t · Cited by 33
Advances in immunotherapy for pancreatic ductal adenocarcinoma
Miyazawa, M., Katsuda, M., Kawai, M., Hirono, S., Okada, K., Kitahata, Y., & Yamaue, H. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.944 · Cited by 33
cGAS-like receptor-mediated immunity: the insect perspective
Cai, H., Meignin, C., & Imler, J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.01.005 · Cited by 33
Increased Toll-like receptor 5 expression indicates esophageal columnar dysplasia
Helminen, O., Huhta, H. I., Takala, H., Lehenkari, P. P., Saarnio, J., Kauppila, J. H., & Karttunen, T. J. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1505-2 · Cited by 32
Cheng, R., Fontana, F., Xiao, J., Liu, Z., Figueiredo, P., Shahbazi, M., Wang, S., Jin, J., Torrieri, G., Hirvonen, J. J., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c15057 · Cited by 32
Zhao, A., Yang, Z., Wang, D., Shi, B., Zhang, H., Bai, Y., Yan, B., Zhang, Y., Wen, J., Wang, X., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202200673rrr · Cited by 32
Seo, Y. D., Lu, H., Black, G., Smythe, K., Yu, Y., Hsu, C., Ng, J., Hermida de Viveiros, P., Warren, E. H., Schroeder, B. A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4015 · Cited by 31
Koga‐Yamakawa, E., Murata, M., Dovedi, S. J., Wilkinson, R. W., Ota, Y., Umehara, H., Sugaru, E., Hirose, Y., Harada, H., Jewsbury, P. J., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1730-4 · Cited by 31
Hu, J., He, Y., Yan, M., Zhu, C., Ye, W.-M., Zhu, H.-G., Chen, W., Zhang, C.-P., & Zhang, Z.-Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058273 · Cited by 31
Attar, M. K. A., Anwar, M. A., Eskian, M., Keshavarz‐Fathi, M., Choi, S., & Rezaei, N. (2017) · Medicinal Research Reviews · doi:10.1002/med.21480 · Cited by 31
Otsuka, T., Nishida, S., Shibahara, T., Temizoz, B., Hamaguchi, M., Shiroyama, T., Kimura, K. B., Miyake, K., Hirata, H., Mizuno, Y., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09818-4 · Cited by 31
IFN Signaling and ICB Resistance: Time is on Tumor’s Side
López‐Soto, A., Gonzalez, S. R., & Folgueras, A. R. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.01.004 · Cited by 30
Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis
Caisová, V., Uher, O., Nedbalová, P., Jochmanová, I., Kvardová, K., Masáková, K., Krejčová, G., Paďouková, L., Chmelař, J., Kopecký, J., et al. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.038 · Cited by 29
Toll‐like receptor 4 regulates spontaneous intestinal tumorigenesis by up‐regulating IL‐6 and GM‐CSF
Shi, Y., Zhao, Q., Liu, X., Dong, S., Jifu, E., Xu, L., Liu, C., & Wang, H. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14742 · Cited by 29
Polymorphisms in STING Affect Human Innate Immune Responses to Poxviruses
Kennedy, R. B., Haralambieva, I. H., Ovsyannikova, I. G., Voigt, E. A., Larrabee, B. R., Schaid, D. J., Zimmermann, M. T., Oberg, A. L., & Poland, G. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.567348 · Cited by 29
Xiong, W., He, W., Wang, T., He, S., Xu, F., Wang, Z., Wang, X., Guo, H., Ling, J., Zhang, H., et al. (2022) · Advanced Science · doi:10.1002/advs.202103029 · Cited by 29
Daßler-Plenker, J., Paschen, A., Putschli, B., Rattay, S., Schmitz, S., Goldeck, M., Bartok, E., Hartmann, G., & Coch, C. (2019) · International Journal of Cancer · doi:10.1002/ijc.31874 · Cited by 28
Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer
Lanki, M., Seppänen, H. E., Mustonen, H. K., Böckelman, C., Juuti, A., Hagström, J., & Haglund, C. H. (2018) · Tumor Biology · doi:10.1177/1010428318801188 · Cited by 28
Glial TLR2‐driven innate immune responses and CD8+ T cell activation against brain tumor
Chang, C. Y., Jeon, S., Yoon, H. J., Choi, B., Kim, S. S., Oshima, M., & Park, E. J. (2019) · Glia · doi:10.1002/glia.23597 · Cited by 28
TNF-α sculpts a maturation process in vivo by pruning tolerogenic dendritic cells
Iberg, C. A., Bourque, J., Fallahee, I., Son, S., & Hawiger, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110657 · Cited by 28
Plasma cell derived mtDAMPs activate macrophage STING pathway which promotes myeloma progression.
Jibril, A. S., Hellmich, C., Wojtowicz, E. E., Hampton, K., Maynard, R. S., Silva, R. D., Fowler-Shorten, D. J., Mistry, J. J., Moore, J. A., Bowles, K. M., et al. (2023) · Blood · doi:10.1182/blood.2022018711 · Cited by 28
Douville, Y., Pelouze, G., Roy, R., Charrois, R., Kibrité, A., Martín, M., Dionne, L., Coulonval, L., & Robinson, J. (1978) · PubMed · Cited by 27
Promotion of Lung Cancer Metastasis by SIRT2‐Mediated Extracellular Protein Deacetylation
Wu, M., Zhang, J., Xiong, Y., Zhao, Y., Zheng, M., Huang, X., Huang, F., Wu, X., Li, X., Fan, W., et al. (2022) · Advanced Science · doi:10.1002/advs.202205462 · Cited by 27
Chan, E. W., Kwak, E. L., Hwang, J., Heiskala, M. K., Bourdonnaye, G. D. L., & Mita, M. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2682-2 · Cited by 26
Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model
Caisová, V., Vieru, A., Kumžáková, Z., Glaserová, S., Husníková, H., Vácová, N., Krejčová, G., Paďouková, L., Jochmanová, I., Wolf, K. I., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2982-x · Cited by 26
Gowing, S. D., Chow, S. C., Cools‐Lartigue, J., Chen, C. B., Najmeh, S., Goodwin-Wilson, M., Jiang, H. Y., Bourdeau, F., Beauchamp, A., Angers, I., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.023 · Cited by 26
Kim, J., Kordahi, M. C., Chac, D., & DePaolo, R. W. (2019) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-19-0286 · Cited by 26
Garon, E. B., Spira, A. I., Johnson, M. L., Bazhenova, L. A., Leach, J., Cummings, A. L., Candia, A. F., Coffman, R. L., Janatpour, M. J., Janssen, R. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0263 · Cited by 26
Zhu, X., Xu, Y., Wang, J., Xue, Z., Qiu, T., & Chen, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1165602 · Cited by 26
Alfaro, V. Y., Goldblatt, D. L., Ha, G. V., Munsell, M. F., Quinton, L. J., Walker, A. K., Dantzer, R., Varadhachary, A., Scott, B. L., Evans, S. E., et al. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00008 · Cited by 25
Liu, Q., Hua, M., Zhang, C., Wang, R., Liu, J., Yang, X., Han, F., Hou, M., & Ma, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.014 · Cited by 25
Goswami, A., Deb, B., Goyal, S., Gosavi, A., Mali, M., Martis, A. M., Khurana, P., Gangar, M., Raykar, D., Mohanty, A., et al. (2022) · Molecules · doi:10.3390/molecules27196721 · Cited by 25
Shi, W., Wang, Q., Bian, Y., Fan, Y., Zhou, Y., Feng, T., Li, Z., & Cao, X. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152604 · Cited by 24
Lasarte-Cía, A., Lozano, T., Cano, D., Martín-Otal, C., Navarro, F. C., Gorraiz, M., Casares, N., Vivas, I., & Lasarte, J. J. (2021) · BioMed Research International · doi:10.1155/2021/8852233 · Cited by 24
CIITA versus IFN-γ induced MHC class II expression in head and neck cancer cells
Meißner, M., Whiteside, T. L., Kaufmann, R., & Seliger, B. (2008) · Archives of Dermatological Research · doi:10.1007/s00403-008-0922-6 · Cited by 23
Manna, S., Maiti, S., Shen, J., Du, W., & Esser-Kahn, A. P. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c01001 · Cited by 23
Halwani, A. S., Panizo, C., Isufi, I., Herrera, A. F., Okada, C. Y., Cull, E. H., Kis, B., Chaves, J. M., Bartlett, N. L., Ai, W. Z., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.2010057 · Cited by 23
Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells
Jiang, X., Lin, J., Shangguan, C., Wang, X., Xiang, B., Chen, J., Guo, H., Zhang, W., Zhang, J., Shi, Y., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci160790 · Cited by 23
Self-citationRolf, N., Kariminia, A., Ivison, S. M., Reid, G. S. D., & Schultz, K. R. (2015) · European Journal of Immunology · doi:10.1002/eji.201444874 · Cited by 22
Rousseau, S., & Martel, G. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00050 · Cited by 21
Li, J., Tang, M., Ke, R.-X., Li, P.-L., Sheng, Z.-G., & Zhu, B. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116765 · Cited by 21
Guey, B., Bodnar‐Wachtel, M., Drouillard, A., Eberhardt, A., Pratviel, M., Goutagny, N., Bendriss‐Vermare, N., Puisieux, I., Caux, C., Walzer, T., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01683 · Cited by 20
The ontogeny of tumor-associated macrophages: a new understanding of cancer-elicited inflammation
Franklin, R. A., & Li, M. O. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955346 · Cited by 19
Kang, J.-H., Lee, H.-J., Lee, J., Hong, J. H., Kim, Y. H., Disis, M. L., Gim, J., & Park, K. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004702 · Cited by 19
Li, S., Yao, J.-C., Li, J. T., Schmidt, A. P., & Link, D. C. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.02.001 · Cited by 18
Ulrich-Lewis, J. T., Draves, K. E., Roe, K., O’Connor, M. A., Clark, E. A., & FULLER, D. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861710 · Cited by 18
Tang, K., McLeod, L., Livis, T., West, A. C., Dawson, R., Yu, L., Balic, J. J., Chonwerawong, M., Wray‐McCann, G., Oshima, H., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.06.002 · Cited by 18
cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma
Tripathi, S., Najem, H., Mahajan, A., Zhang, P., Low, J., Stegh, A. H., Curran, M. A., Ashley, D. M., James, C. D., & Heimberger, A. B. (2022) · F1000Research · doi:10.12688/f1000research.125163.1 · Cited by 17
Ouyang, B., Pan, N., Zhang, H., Xing, C., & Ji, W. (2021) · Oncology Reports · doi:10.3892/or.2021.7966 · Cited by 16
Banerjee, M., Basu, S., Middya, S., Shrivastava, R., Ghosh, R., Pryde, D. C., Yadav, D. B., Bhattacharya, G., Soram, T., Puniya, K., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-lb-061 · Cited by 15
STING cg16983159 methylation: a key factor for glioblastoma immunosuppression
Qiu, L., Meng, Y., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01093-w · Cited by 15
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
Álvarez, M., Molina, C., Garasa, S., Ochoa, M. C., Rodriguez-Ruiz, M. E., Gomis, G., Cirella, A., Olivera, I., Glez‐Vaz, J., González-Gomariz, J., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2197370 · Cited by 15
Rogava, M., Braun, A. D., van der Sluis, T. C., Shridhar, N., Tüting, T., & Gaffal, E. (2021) · International Journal of Cancer · doi:10.1002/ijc.33804 · Cited by 13
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors
Lee, S., Yagita∥, H., Sayers, T. J., & Celis, E. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0834-0 · Cited by 12
NLRP6 targeting suppresses gastric tumorigenesis via P14ARF–Mdm2–P53-dependent cellular senescence
Wang, H., Xu, G., Huang, Z., Li, W., Cai, H., Zhang, Y., Xiong, D., Liu, G., Wang, S., Xue, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22876 · Cited by 12
Ren, L., Guo, D., Wan, X., & Qu, R. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab001 · Cited by 11
Deleting MyD88 signaling in myeloid cells promotes development of adenocarcinomas of the colon
Song, J., Chen, Z., Geng, T., Wang, M., Yi, S., Liu, K., Zhou, W., Gao, J., Song, W., & Tang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.036 · Cited by 10
Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis
Bufalieri, F., Basili, I., Marcotullio, L. D., & Infante, P. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.710171 · Cited by 10
Knoll, M., Waltenberger, M., Furkel, J., Wirkner, U., Ward, A., Đokić, I., Schwager, C., Adeberg, S., Rieken, S., Keßler, T., et al. (2022) · Cancers · doi:10.3390/cancers14030684 · Cited by 10
Cited by
Huynh, T. M. H., Huang, P.-X., Wang, K.-L., Tran, N.-T., Iao, H. M., Pan, W.-C., Chang, Y.-H., Lien, H.-W., Lee, A. Y.-L., Chou, T.-C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c05395 · Cited by 122
Neutrophils and Neutrophil-Based Drug Delivery Systems in Anti-Cancer Therapy
Wahnou, H., El Kebbaj, R., Hba, S., Ouadghiri, Z., El Faqer, O., Pinon, A., Liagre, B., Limami, Y., & Duval, R. E. (2025) · Cancers · doi:10.3390/cancers17071232 · Cited by 35
Immunogenic cell death mediated TLR3/4-activated MSCs in U87 GBM cell line
Emami Meybodi, S. M., Moradi Moraddahande, F., & Dehghani Firoozabadi, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29858 · Cited by 3
Metadata
- Authors
- Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-03-25
- Volume
- 9
- Issue
- 1
- Pages
- 68-68
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4394738965
- Cited by
- 255
- References
- 670
- FWCI
- 38.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.